Skip to main content

Table 2 The susceptibility results of Abs in vitro

From: Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia

 

Total

(n = 166)

Death group

(n = 45)

Survival group

(n = 121)

 

S

I

S

I

S

I

Ampicillin/sulbactam

3/166

8/166

1/45

0/45

2/121

8/121

Piperacillin

0/166

0/166

0/45

0/45

0/121

0/121

Carbapenems*

9/166

0/166

4/45

0/45

5/121

0/121

Piperacillin/Tazobactam

1/166

3/166

0/45

0/45

1/121

3/121

Ceftriaxone

0/166

4/166

0/45

1/45

0/121

3/121

Cefotaxime

0/166

4/166

0/45

1/45

0/121

3/121

Cefepime

2/166

3/166

1/45

1/45

1/121

2/121

Cefoxitin

0/166

0/166

0/45

0/45

0/121

0/121

Gentamicin

7/166

4/166

2/45

1/45

5/121

3/121

Tobramycin

15/166

2/166

3/45

1/45

12/121

1/121

Amikacin

12/166

1/166

3/45

0/45

9/121

1/121

Ciprofloxacin

4/166

0/166

1/45

0/45

3/121

0/121

Levofloxacin

4/166

7/166

1/45

0/45

3/121

7/121

Moxifloxacin

4/166

0/166

1/45

0/45

3/121

0/121

Tetracycline

3/166

6/166

1/45

0/45

2/121

6/121

Tigecycline

161/166

5/166

44/45

1/45

117/121

4/121

Trimethoprim/Sulfamethoxazole

17/166

0/166

5/45

0/45

12/121

0/121

Cefoperazone/Sulbactam

3/166

7/166

1/45

2/45

2/121

5/121

Minocyclline

25/166

13/166

4/45

2/45

21/121

11/121

Ampicillin

1/166

0/166

0/45

0/45

1/121

0/121

Amoxicillin/Clavulanic

6/166

0/166

2/45

0/45

4/121

0/121

Aztreonam

7/166

0/166

3/45

0/45

4/121

0/121

Cefotetan

1/166

0/166

1/45

0/45

0/121

0/121

Cefazolin

0/166

0/166

0/45

0/45

0/121

0/121

  1. *Carbapenems including Imipenem/Meropenem/Doripenem